Form 4: Ionis Pharmaceuticals Director Joseph H. Wender Reports Stock Vesting

Director Joseph H. Wender reports the vesting of restricted stock units into Ionis Pharmaceuticals common stock.

Summary

• On July 15, 2024, Joseph H. Wender, a director of Ionis Pharmaceuticals, reported the vesting of 4,677 shares of common stock related to restricted stock units.
• These shares were acquired at a price of $0.00 as part of the vesting and release of shares from a Restricted Stock Unit award.
• Following the transaction, Wender beneficially owns 132,756 shares indirectly through a trust and 4,079 derivative securities directly.

Sentiment

Score: 5

Explanation: This is a neutral report on stock vesting, a routine part of executive compensation. It doesn't inherently indicate positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, common in the pharmaceutical industry.

Comparison to Industry Standards

• Stock vesting schedules and equity compensation are standard practice across the pharmaceutical industry to align executive incentives with company performance.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize restricted stock units as part of their compensation packages for directors and executives.
• The vesting terms described are fairly typical, with vesting often tied to service duration or specific company milestones.

Key Dates